Interferon-β1a protects neurons against mitochondrial toxicity via modulation of STAT1 signaling: Electrophysiological evidence

Neurobiology of Disease

Volumn 62, Issue , 2014, Pages 387-393

  Di Filippo, Massimiliano ^a   Tozzi, Alessandro ^a,b   Tantucci, Michela ^a   Arcangeli, Sara ^a,c   Chiasserini, Davide ^a   Ghiglieri, Veronica ^b   De Iure, Antonio ^a   Calabresi, Paolo ^a,b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Inflammation; Interferon 1a; Mitochondria; Multiple sclerosis; Neurodegeneration; Rotenone

Indexed keywords

BETA1A INTERFERON; DOPAMINE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE P38; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); STAT1 PROTEIN;

ALLERGIC ENCEPHALOMYELITIS; AMPLITUDE MODULATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ELECTROPHYSIOLOGY; BRAIN NERVE CELL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; FEMALE; INHIBITION KINETICS; INTRACELLULAR SIGNALING; LOW DRUG DOSE; MALE; MITOCHONDRIAL TOXICITY; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; RAT; STRIATE CORTEX;

INFLAMMATION; INTERFERON-Β1A; MITOCHONDRIA; MULTIPLE SCLEROSIS; NEURODEGENERATION; ROTENONE;

ANIMALS; CORPUS STRIATUM; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; INTERFERON-BETA; MICE; MICE, INBRED C57BL; MITOCHONDRIA; MULTIPLE SCLEROSIS; NEURONS; NEUROPROTECTIVE AGENTS; RATS; ROTENONE; STAT1 TRANSCRIPTION FACTOR; UNCOUPLING AGENTS;

EID: 84887527163     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.09.022     Document Type: Article

References (39)

1. Al-Izki S., Pryce G., O'Neill J.K., Butter C., Giovannoni G., Baker D. Practical guide to the induction of relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse. Mult. Scler. Relat. Dis. 2012, 1:29-38.
2. Amor S., Smith P.A., Hart B'., Baker D. Biozzi mice: of mice and human neurological diseases. J. Neuroimmunol. 2005, 165(1-2):1-10.
3. Anderson V.M., Fox N.C., Miller D.H. Magnetic resonance imaging measures of brain atrophy in multiple sclerosis. J. Magn. Reson. Imaging 2006, 23(5):605-618.
4. Beyer S., Raether G., Stadler K., Hoffrogge R., Scharf C., Rolfs A., Mix E., Strauss U. Interferon-beta modulates protein synthesis in the central nervous system. J. Neuroimmunol. 2009, 213(1-2):31-38.
5. Calabresi P., Picconi B., Tozzi A., Di Filippo M. Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci. 2007, 30(5):211-219.
6. Campbell G.R., Ziabreva I., Reeve A.K., Krishnan K.J., Reynolds R., Howell O., Lassmann H., Turnbull D.M., Mahad D.J. Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis. Ann. Neurol. 2011, 69(3):481-492.
7. Centonze D., Prosperetti C., Barone I., Rossi S., Picconi B., Tscherter A., De Chiara V., Bernardi G., Calabresi P. NR2B-containing NMDA receptors promote the neurotoxic effects of 3-nitropropionic acid but not of rotenone in the striatum. Exp. Neurol. 2006, 202(2):470-479.
8. Chang L., Karin M. Mammalian MAP kinase signalling cascades. Nature 2001, 410(6824):37-40.
9. Ciccarelli O., Toosy A.T., De Stefano N., Wheeler-Kingshott C.A., Miller D.H., Thompson A.J. Assessing neuronal metabolism in vivo by modeling imaging measures. J. Neurosci. 2010, 30(45):15030-15033.
10. Compston A., Coles A. Multiple sclerosis. Lancet 2008, 372(9648):1502-1517.
11. Costa C., Belcastro V., Tozzi A., Di Filippo M., Tantucci M., Siliquini S., Autuori A., Picconi B., Spillantini M.G., Fedele E., Pittaluga A., Raiteri M., Calabresi P. Electrophysiology and pharmacology of striatal neuronal dysfunction induced by mitochondrial complex I inhibition. J. Neurosci. 2008, 28(32):8040-8052.
12. Darnell J.E., Kerr I.M., Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264(5164):1415-1421.
13. Dhib-Jalbut S., Marks S. Interferon-beta mechanisms of action in multiple sclerosis. Neurology 2010, 74(Suppl. 1):S17-S24.
14. Di Filippo M., Picconi B., Costa C., Bagetta V., Tantucci M., Parnetti L., Calabresi P. Pathways of neurodegeneration and experimental models of basal ganglia disorders: downstream effects of mitochondrial inhibition. Eur. J. Pharmacol. 2006, 545(1):65-72.
15. Di Filippo M., Anderson V.M., Altmann D.R., Swanton J.K., Plant G.T., Thompson A.J., Miller D.H. Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes. J. Neurol. Neurosurg. Psychiatry 2010, 81(2):204-208.
16. Di Filippo M., Chiasserini D., Tozzi A., Picconi B., Calabresi P. Mitochondria and the link between neuroinflammation and neurodegeneration. J. Alzheimers Dis. 2010, 20(Suppl. 2):S369-S379.
17. Dutta R., Trapp B.D. Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog. Neurobiol. 2011, 93(1):1-12.
18. Dutta R., McDonough J., Yin X., Peterson J., Chang A., Torres T., Gudz T., Macklin W.B., Lewis D.A., Fox R.J., Rudick R., Mirnics K., Trapp B.D. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann. Neurol. 2006, 59(3):478-489.
19. Duty S., Jenner P. Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br. J. Pharmacol. 2011, 164(4):1357-1391.
20. Fisniku L.K., Chard D.T., Jackson J.S., Anderson V.M., Altmann D.R., Miszkiel K.A., Thompson A.J., Miller D.H. Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann. Neurol. 2008, 64(3):247-254.
21. Frank D.A., Mahajan S., Ritz J. Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat. Med. 1999, 5(4):444-447.
22. Goodin D.S. Disease-modifying therapy in multiple sclerosis: update and clinical implications. Neurology 2008, 71(24 Suppl 3):S8-S13.
23. Jin S., Kawanokuchi J., Mizuno T., Wang J., Sonobe Y., Takeuchi H., Suzumura A. Interferon-beta is neuroprotective against the toxicity induced by activated microglia. Brain Res. 2007, 1179:140-146.
24. Lekmine F., Uddin S., Sassano A., Parmar S., Brachmann S.M., Majchrzak.B., Sonenberg N., Hay N., Fish E.N., Platanias L.C. Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons. J. Biol. Chem. 2003, 278(30):27772-27780.
25. Mahad D., Ziabreva I., Lassmann H., Turnbull D. Mitochondrial defects in acute multiple sclerosis lesions. Brain 2008, 131(Pt 7):1722-1735.
26. Mahad D.J., Ziabreva I., Campbell G., Lax N., White K., Hanson P.S., Lassmann H., Turnbull D.M. Mitochondrial changes within axons in multiple sclerosis. Brain 2009, 132(Pt 5):1161-1174.
27. Picconi B., Centonze D., Håkansson K., Bernardi G., Greengard P., Fisone G., Cenci M.A., Calabresi P. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat. Neurosci. 2003, 6:501-506.
28. Platanias L.C. The p38 mitogen-activated protein kinase pathway and its role in interferon signaling. Pharmacol. Ther. 2003, 98(2):129-142.
29. Platanias L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 2005, 5(5):375-386.
30. Reyes-Vázquez C., Prieto-Gómez B., Dafny N. Interferon modulates central nervous system function. Brain Res. 2012, 1442:76-89.
31. Santos R., Weinstock-Guttman B., Tamaño-Blanco M., Badgett D., Zivadinov R., Justinger T., Munschauer, F., Ramanathan M. Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies. J. Neuroimmunol. 2006, 176(1-2):125-133.
32. Trapp B.D., Stys P.K. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol. 2009, 8(3):280-291.
33. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mörk S., Bö L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 1998, 338(5):278-285.
34. van Horssen J., Witte M.E., Ciccarelli O. The role of mitochondria in axonal degeneration and tissue repair in MS. Mult. Scler. 2012, 18(8):1058-1067.
35. Waxman S.G. Axonal conduction and injury in multiple sclerosis: the role of sodium channels. Nat. Rev. Neurosci. 2006, 7(12):932-941.
36. Weinstock-Guttman B., Badgett D., Patrick K., Hartrich L., Santos R., Hall D., Baier M., Feichter J., Ramanathan M. Genomic effects of IFN-beta in multiple sclerosis patients. J. Immunol. 2003, 171(5):2694-2702.
37. Witte M.E., Geurts J.J., de Vries H.E., van der Valk P., van Horssen J. Mitochondrial dysfunction: a potential link between neuroinflammation and neurodegeneration?. Mitochondrion 2010, 10(5):411-418.
38. Zivadinov R., Locatelli L., Cookfair D., Srinivasaraghavan B., Bertolotto A., Ukmar M., Bratina A., Maggiore C., Bosco A., Grop A., Catalan M., Zorzon M. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy. Mult. Scler. 2007, 13(4):490-501.
39. Zula J.A., Green H.C., Ransohoff R.M., Rudick R.A., Stark G.R., van Boxel-Dezaire A.H. The role of cell type-specific responses in IFN-β therapy of multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(49):19689-19694.